2016
Eylea sales jump helps boost Regeneron in Q2 results
August 5, 2016Medical Communications, Research and Development 2016, Eylea, Q2, Regeneron, results
Regeneron Pharmaceuticals has published positive Q2 results with a 27% rise in Eylea (aflibercept) sales in the US helping to …
Revenue rises at Pfizer as Ibrance and Xeljanz beat sales expectations
August 2, 2016Research and Development, Sales and Marketing 2016, Pfizer, Prevnar, Q2, Xeljanz, ibrance, results
Pfizer has published its Q2 results, which show revenues rising 11% with new drugs helping to drive the growth and …
Earnings drop at Sanofi as it looks for a quick Medivation resolution
July 29, 2016Medical Communications, Research and Development 2016, Medivation, Q2, Sanofi, earnings
Sanofi has published its earnings results for Q2, which show a fall in sales and profits as their diabetes division …
Cholesterol drugs drag AstraZeneca’s profits down in latest financial results
July 28, 2016Research and Development, Sales and Marketing 2016, AstraZeneca, Q2, h1, results
AstraZeneca has maintained its financial outlook for 2016, despite its Q2 and H1 results showing sharp falls in core earnings …
Gilead lowers full-year guidance as sales and profits down in Q2
July 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Gilead, Q2, results
Gilead Sciences has announced its financial results from the second quarter of this year, with sales and profits taking a …
Roche beats forecasts in strong H1 results
July 21, 2016Research and Development, Sales and Marketing 2016, Q2, Roche, h1, results
Roche has published very encouraging full results for the first half of this year, with cancer drug sales helping to …
J&J boosted by pharma revenue in Q2 results
July 20, 2016Research and Development 2016, Johnson and Johnson, Q2, results
Shares at Johnson and Johnson have reached a record high of over $125 after pharma revenues helped to raise full …
Novartis lowers core operating profit outlook in Q2 results
July 19, 2016Manufacturing and Production, Research and Development, Sales and Marketing 2016, Novartis, Q2, results
Novartis has warned that its profits may decline this year as it issued second quarter results, with generic competition for …
Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%
April 29, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results
Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
